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Summary
Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. They can be 
classified according to pathological, radiological or clinical behaviour as typical, atypical or carcinomas, invasive  
or noninvasive, and aggressive or nonaggressive. Prolactinomas account for 40–60% of all pituitary adenomas,  
with dopamine agonists representing the first-line treatment and surgery/radiotherapy reserved for drug 
intolerance/resistance or in neuro-ophthalmological emergencies. We present the case of a 62-year-old man with 
an apparently indolent prolactin-secreting macroadenoma managed with partial resection and initially showing 
a biochemical response to cabergoline. Five years later, the tumour became resistant to cabergoline, despite a 
substantial increase in dosage, showing rapid growth and causing worsening of vision. The patient then underwent 
two further transsphenoidal operations and continued on high-dose cabergoline; despite these interventions, 
the tumour continued enlarging and prolactin increased to 107 269 U/L. Histology of the third surgical specimen 
demonstrated features of aggressive behaviour (atypical adenoma with a high cell proliferation index) not present  
in the tumour removed at the first operation. Subsequently, he was referred for radiotherapy aiming to control 
tumour growth.
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Learning points:
•	 The development of secondary resistance to dopamine agonists (DAs) is a serious sign as it may be associated with 
de-differentiation of the prolactinoma and thus of aggressive or malignant transformation.
•	 Significant de-differentiation of the adenoma documented on consecutive histologies suggests a possible transition 
to malignancy.
•	 A combination of histological ‘alarm’ features associated with persistent growth and escape from DAs treatment in 
recurrent adenomas should alert clinicians and demands close follow-up.
•	 A multidisciplinary approach by pathologists, endocrinologists and neurosurgeons is essential.
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Background
Pituitary tumours are a relatively common intracranial 
neoplasm. Approximately 10–20% of the normal 
population may harbour these lesions according to 
autopsy and/or pituitary magnetic resonance imaging 
(MRI) series: most of these tumours are clinically 
insignificant with less than 5 mm in diameter and 
grow slowly over many years without local invasion 
or remain static. Prolactinomas account for 40–60% of 
all pituitary adenomas and up to 80% are present as 
microadenomas (1). Pituitary adenomas can be classified 
according to pathological, radiological or clinical 
behaviour as typical, atypical and carcinomas, invasive 
or noninvasive, and aggressive or nonaggressive: 
using the WHO 2004 classification (currently under 
revision), the majority are typical adenomas. They 
are slow-growing, well-demarcated, noninvasive 
adenomas, showing no major cellular and nuclear 
pleomorphism, few mitotic figures and a Ki-67 nuclear 
index <3%. Atypical adenomas are tumours that 
demonstrate a Ki-67 nuclear index >3%, elevated 
mitotic activity and excessive p53 immunoreactivity 
(2). Pituitary carcinomas can only be diagnosed 
if cerebrospinal and/or systemic metastases are 
documented.
First-line therapy for prolactinomas are dopamine 
agonists (DAs): these agents are effective in controlling 
clinical symptoms, normalising serum prolactin 
(PRL) and reducing tumour volume, while being 
well tolerated. Surgery and radiotherapy are reserved 
for drug-resistant tumours or intolerance to DAs or 
neuro-ophthalmological emergencies.
We present a patient with a macroprolactinoma who 
showed an unexpected and severe escape from cabergoline 
treatment. The tumour was originally a typical adenoma 
sensitive to DAs therapy, but later it became resistant to 
the DA and transformed into an atypical adenoma with 
aggressive features.
Case presentation
A 62-year-old man presented with collapse in August 
2008. His admission was preceded by a one-year history 
of general lethargy/malaise, weight loss, deteriorating 
vision and loss of chest and pubic hair. His medical 
history included a pelvic sarcoma excised in 2001 
followed by radiotherapy, and a fluctuating PSA on 
surveillance (biopsy in 2011 revealed no evidence 
of malignancy).
Investigations
On presentation, he had a serum PRL of 55  287 U/L 
(reference range 45–375 U/L) without significant 
macroprolactin identified, LH 0.1 IU/L (1.5–9.3), FSH 
0.4 IU/L (2–20), testosterone <0.4 nmoL/L (8.4–28.7), 
IGF-1 6.6 nmoL/L (7.2–27.6), TSH 1.34 U/L (0.35–5.4), 
FT4 6.6 pmol/L (10.5–20) and cortisol 111 nmol/L at 
0900 h and normal serum and urinary osmolalities. MRI 
revealed a 2.1 × 2.4 × 2.5 cm pituitary mass with marked 
suprasellar extension and compression of the optic 
chiasm, with areas of high T1-weighted signal suggesting 
possible apoplexy. Visual field testing was consistent with 
bitemporal hemianopia.
Treatment
The patient underwent transsphenoidal adenomectomy 
(TSA) on August 2008 with an uneventful post-operative 
course and resolution of his visual field defect. Pathology 
identified features of a pituitary adenoma with rare 
mitotic figures, overall Ki-67 nuclear index ~3%, only 
weak expression of p53 and no other features of atypia. 
Immunohistochemistry showed expression of PRL by the 
majority of cells (Fig. 1).
Outcome and follow-up
Post-operatively, serum PRL decreased, although it 
remained significantly elevated (Fig.  2) but normalised 
later on cabergoline (Fig.  2). Appropriate hormone 
Figure 1
Histologic slides of first biopsy. (A) Haematoxylin and eosin, (B) PRL 
expression, (C) Ki-67 expresstion, (D) p53 expression.
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replacement was initiated (hydrocortisone, l-thyroxine 
and testosterone gel). An MRI performed one year after 
surgery demonstrated a 5 mm rim of soft tissue along the 
floor of the pituitary fossa without compression of the 
optic chiasm.
The patient remained stable over the next 5 years 
(Fig.  2 shows PRL levels in relation to surgery and 
changes in cabergoline dose). However, in February 
2014, serum PRL started increasing, and in December 
2014, the patient reported deterioration of his vision, 
confirmed by visual field examination. At this stage, 
his MRI demonstrated tumour growth (mass of 21 mm 
within the expanded sella, which slightly elevated the 
optic chiasm), and the patient underwent a second TSA 
for debulking: the tumour was found to be soft and 
semi-liquid. Histological examination identified a tiny 
tissue fragment showing PRL expression, consistent 
with the original pathology. After surgery, the patient 
had slight improvement in his vision and continued 
on cabergoline. In the following months, despite 
good compliance with the DAs, he developed further 
visual deterioration with bitemporal hemianopia. 
The MRI revealed progressive enlargement of the 
large macroadenoma (27 mm) with increased superior 
elevation and distortion of the optic chiasm. The 
patient underwent a further debulking, and histology 
showed strong diffuse positivity for PRL and weak 
focal staining for LH, but with features of an atypical 
pituitary adenoma (mammotroph/prolactinoma) with 
a very high mitotic index (9–10 per 10 HP fields) and a 
Ki-67 index of 20–30%. Most tumour cell nuclei showed 
moderate-to-strong nuclear staining for p53 (Fig.  3). 
PRL after surgery was 29  455 U/L, and the patient is 
currently undergoing external beam radiotherapy, 
45 Gy in 25 fractions.
Discussion
Our case shows a combination of features indicative of 
a non-benign clinical course, such as persistent growth 
requiring multiple operations, secondary resistance to DA 
therapy and transformation to an atypical histology over 
5 years.
A variety of definitions of DA resistance have been 
proposed. The most commonly used definition includes 
failure to achieve normoprolactinaemia (biochemical 
response) and/or failure to achieve at least 50% shrinkage 
(tumour response) with maximal conventional doses of 
medication (bromocriptine 7.5 mg/day or cabergoline 
2.0 mg/week) (3). When non-compliance is ruled out, 
as seems likely in this case, escape from initial control 
may be associated with de-differentiation of the tumour 
and thus the potential for malignant transformation. 
Indeed, tumours very sensitive to DAs are more likely to 
show persistent remission of hyperprolactinaemia after 
treatment withdrawal (4), whereas tumours less responsive 
to medical therapy, as here, often express histological 
markers of increased cell proliferation and may show a 
turbulent clinical course.
Recently, questions regarding the legitimacy and 
utility of the WHO 2004 classification for pituitary 
adenomas have invoked some controversy following its 
initial description. Lately, a German group further specifed 
Figure 2
PRL level according to surgery and variations in cabergoline dose. inc, 
increased; red, reduced. Figure 3
Histologic slides of third biospy. (A) Haematoxylin and eosin, (B) PRL 
expression, (C) Ki-67 expression, (D) p53 expression.
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certain histomorphological and immunohistochemical 
parameters for the diagnosis of an atypical adenoma 
(APA) using the German pituitary adenoma registry. They 
defined a cutoff value for the number of mitotic figures as 
≥2 mitoses per 10 high power fields (HPFs) and a p53 ≥2% 
in APA cases. Moreover, according to this study, the best 
marker for differentiating typical pituitary adenomas and 
APAs is a Ki-67 nuclear index >4% (5). Others reported 
that the presence of p53 in combination with increased 
Ki-67% is probably superior to either method alone (6).
Others have also pointed out that the 2004 
WHO classification does not take into account the 
invasive status of the tumour and that its numerous 
ultrastructural subtypes are confusing (7). A French 
multicentric collaborative study recently published a 
clinicopathological classification of pituitary adenomas, 
which relies on proliferation markers, invasion into the 
cavernous and sphenoid sinus and tumour size (7). To 
confirm invasiveness, the authors suggested histological 
and/or radiological signs of cavernous or sphenoid sinus 
invasion. For the assessment of cell proliferation, they 
used the presence of at least two markers with cutoff 
values of 3% for the Ki-67 index (with formol fixative 
and 1% for Bouin-Hollande fixative), mitoses >2 per 
10 HPFs and positivity for p53 in at least 10 nuclei per 
10 HPFs (7). These questions are being addressed in the 
latest WHO assessment, where the current classification 
is likely to be modified.
However, our patient showed a change in tumour 
pathology over time: originally, it was a typical 
adenoma, with few atypical features, changing from 
rare mitotic figures to 9–10 per 10 HPFs, from a Ki-67 
index of 3–5% to 20–30%, and from only weak 
expression of p53 to a moderate-to-strong nuclear 
staining for p53, suggesting a possible transition to a 
highly aggressive phenotype. This is in accord with the 
concept that pituitary carcinomas mainly arise from the 
transformation of initially benign adenomas, although 
de novo development cannot be excluded. In general, 
highly aggressive transformation, including that to 
a carcinoma, is rare, and mainly occurs in PRL- and 
ACTH-secreting tumours, possibly because these 
tumours are less likely to show markers of senescence 
compared with those of other adenoma types (8). 
If further progression occurs in our patient, we will 
consider the option of temozolomide (9, 10). In fact, 
various chemotherapy regimens have been proposed 
for highly aggressive pituitary tumours and carcinomas, 
and temozolomide, an orally administered alkylating 
agent, is becoming the mainstream choice. The outcome 
of treatment might depend on the expression of 
O(6)-methylguanine-DNA methyltransferase (MGMT), 
a DNA repair enzyme that potentially interferes with 
drug efficacy. Furthermore, some encouraging data with 
pasireotide, a somatostatin analogue that exhibit a high 
affinity for the majority of somatostatin receptors, have 
been reported (6, 9, 10).
Most importantly, in such complex cases, 
multidisciplinary collaboration between pathologists, 
endocrinologists, neurosurgeons, neuro-ophthalmologists 
and oncologists is essential offering a holistic approach 
and more optimal outcomes.
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